Related Experiment Videos

[Effects of incretin on cardiovascular disease and risk factors]

Kazuhisa Kodama1, Koichi Node

  • 1Department of Cardiovascular and Renal Medicine, Saga University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 21, 2011
PubMed

Insights

New diabetes drugs like GLP-1 agonists and DPP-4 inhibitors may improve cardiovascular health. These incretin-based therapies show promise for managing diabetes and reducing heart disease risk.

Area of Science:

  • Endocrinology and Metabolism
  • Cardiovascular Medicine

Context:

  • Diabetes mellitus is a significant risk factor for poor outcomes in patients with ischemic heart disease and other cardiovascular diseases.
  • Emerging evidence suggests novel diabetes pharmacotherapies possess cardioprotective properties.

Purpose:

  • To review the cardiovascular effects of incretin-based therapies, including glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors.
  • To evaluate the potential of these agents in mitigating cardiovascular risk in diabetic patients.

Summary:

  • Incretin-based therapies demonstrate multifaceted benefits beyond glycemic control.
  • GLP-1 agonists and DPP-4 inhibitors have shown potential to improve cardiovascular risk profiles and prognosis in individuals with diabetes.
  • These agents influence various cardiovascular pathways, contributing to their beneficial effects.

Impact:

  • Incretin therapies represent a promising therapeutic strategy for managing cardiovascular risk in the growing diabetic population.
  • This review highlights the importance of considering cardiovascular outcomes when selecting diabetes treatments.
  • Further research into the cardiovascular mechanisms of incretins may lead to novel treatment paradigms for both diabetes and heart disease.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Regulation of the Cardiovascular System01:27

Regulation of the Cardiovascular System

The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...